Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BI-1206
- Development stage
- Phase 2
- Lead developer
- BioInvent International
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous, Subcutaneous
01
Overview
BI-1206 is a fully human immunoglobulin G1 monoclonal antibody that targets the Fc gamma receptor IIb (CD32b, also known as FcγRIIB) on B cells. By binding to CD32b, it blocks this inhibitory receptor and enhances immune-mediated killing of malignant B cells. This mechanism can restore or enhance the efficacy of other anti-cancer antibodies such as rituximab by preventing their internalization and degradation, thereby increasing their availability to mediate antibody-dependent cell cytotoxicity. BI-1206 is being developed primarily for hematological malignancies including non-Hodgkin's lymphoma (NHL), follicular lymphoma, mantle cell lymphoma, chronic lymphocytic leukemia (CLL), and has also been studied in solid tumors in combination with pembrolizumab. The drug has received orphan drug designation for follicular lymphoma and mantle cell lymphoma[1][2][3][7].
- Other names
- 6G11
02
Targets
FCGR2B (Fc gamma receptor IIB)
Beyond the preview
Go deeper on BI-1206.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BI-1206.